Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis.

@article{Mastrangelo1993CriticalOO,
  title={Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis.},
  author={Renato Mastrangelo and Anna Lasorella and Antonio Iavarone and Vittoria Rufini and Luigi Troncone and Francesco M. Danza and Riccardo Riccardi},
  journal={Medical and pediatric oncology},
  year={1993},
  volume={21 6},
  pages={411-5}
}
Results of treatment with 131-I-Metaiodobenzylguanidine (131-I-MIBG) in patients with resistant neuroblastoma appear encouraging if one considers that most of the patients had far advanced, intensively pre-treated disease. To further explore the potential role of this new drug in untreated patients, we treated 3 children with stage III neuroblastoma. All three of our cases received 131-I-MIBG at relatively low dose with the complete disappearance of the tumor mass in case 1, whereas in cases 2… CONTINUE READING